Concepedia
Statistics
Publications
12
Citations
770
H-Index
Active since
1999
Affiliations
Nexen (Canada)(Current)
University of Washington
Fred Hutch Cancer Center
IDEX Corporation (United States)
Don B. Axworthy is an author at Nexen (Canada) specializing in oncology, cancer immunotherapy, and medicine.
Publications per year
1999–2011
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Andres Forero, Paul L. Weiden, Julie M. Vose et al. · Blood · 2004 · 152 citations · Full text
Medicine, Immunology, Oncology +13
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
Oliver W. Press, Melissa C. Corcoran, Krishnan Subbiah et al. · Blood · 2001 · 149 citations · Full text
Medicine, Hematology, Oncology +14
Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results
Paul L. Weiden, Hazel B. Breitz, Oliver W. Press et al. · Cancer Biotherapy and Radiopharmaceuticals · 2000 · 137 citations
Medicine, Oncology, Pharmacokinetics +17
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Krishnan Subbiah, Don K. Hamlin, John M. Pagel et al. · PubMed · 2003 · 68 citations
Medicine, Oncology, Pharmacology +17
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator
Fu‐Min Su, Paul L. Beaumier, Don B. Axworthy et al. · Nuclear Medicine and Biology · 2005 · 60 citations
Medicine, Nuclear Medicine, Oncology +10
1–5 of 12